Over 15 years have passed since the FDA approved a new fibromyalgia treatment… until now. If you’re wondering whether cyclobenzaprine represents a genuine breakthrough for fibromyalgia patients, the answer is more nuanced than you might think. TONMYA, a sublingual formulation of cyclobenzaprine HCl, has just received FDA approval as the first new fibromyalgia treatment in over 15 years, and it’s being marketed as first-in-class. But here’s what makes it different – this isn’t your typical cyclobenzaprine muscle relaxer. The sublingual delivery bypasses first-pass metabolism, which means you’re getting a unique pharmacological profile that targets specific neurotransmitters thought to be involved in fibromyalgia pain. Clinical trials showed that TONMYA significantly reduced daily pain scores compared to placebo, and it’s taken just once daily at bedtime. So while cyclobenzaprine itself isn’t new, this particular formulation and its application for fibromyalgia represent something genuinely novel for the estimated 10 million Americans living with this chronic pain condition.
Key Takeaways:
- Many people think cyclobenzaprine is just another muscle relaxer, but TONMYA actually represents the first FDA-approved fibromyalgia treatment in over 15 years. It’s not technically “first-in-class” for cyclobenzaprine itself – that’s been around for decades – but this sublingual formulation is a first-in-class approach that works differently than the old oral versions.
- TONMYA works as what’s called a multifunctional agent, hitting 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors. That’s a mouthful, but basically it means it’s tackling pain amplification in the central nervous system from several angles simultaneously – pretty different from the single-target approaches we’ve seen before.
- The clinical trial results showed real improvements that matter to patients. Across two Phase 3 trials with nearly 1,000 participants, TONMYA significantly reduced daily pain scores at 14 weeks compared to placebo.
- Side effects are mostly related to the sublingual delivery method and tend to be manageable. The most common issues include oral numbness, mouth discomfort, weird taste, drowsiness (which makes sense for a bedtime medication), and mouth tingling.
- For the estimated 10 million Americans living with fibromyalgia – about 80% of whom are women – this represents the first new treatment option in more than a decade and a half. That’s a pretty significant development for a patient population that’s been dealing with limited options for way too long.
What’s the Buzz About Cyclobenzaprine as a Fibro Treatment?
The fibromyalgia community has been buzzing since TONMYA hit pharmacy shelves nationwide in November 2025. And honestly? The excitement is justified. You’re looking at the first FDA-approved fibromyalgia treatment in more than 15 years – that’s not just a minor update to an existing drug or a new indication for something you’ve already tried. This is genuinely new territory for fibro patients who’ve been cycling through the same three medications approved way back in the late 2000s.
What makes this moment particularly significant is that TONMYA represents a first-in-class, non-opioid analgesic specifically designed to tackle your widespread pain while you sleep. It’s now available by prescription at pharmacies across the United States, giving an estimated 10 million Americans living with fibromyalgia access to a treatment option that works differently than anything currently on the market. The drug targets multiple neurotransmitter systems thought to be involved in fibromyalgia’s pain amplification – but we’ll get into those specifics in a bit.
A Brief History of Fibromyalgia Treatments
Your current treatment options for fibromyalgia have been pretty limited, and they’ve stayed that way for a really long time. The FDA approved three medications specifically for fibromyalgia between 2007 and 2009: Lyrica (pregabalin), Cymbalta (duloxetine), and Savella (milnacipran). Since then? Radio silence. For over 15 years, you’ve had no new FDA-approved options if those three didn’t work for you or caused side effects you couldn’t tolerate. Many of you have been managing fibro with off-label medications, pain management strategies, and lifestyle modifications – basically making do with what’s available rather than what’s ideal.
The drought in fibromyalgia drug development hasn’t been for lack of trying… It’s just that this condition is incredibly complex to treat. Fibromyalgia involves amplified sensory and pain signalling in your central nervous system, and it comes with a whole package of symptoms beyond pain – nonrestorative sleep, crushing fatigue, cognitive dysfunction, and mood disturbances. Finding a medication that addresses the core symptom of widespread pain without making everything else worse has proven challenging. That’s why TONMYA’s approval in August 2025 marked such a significant shift – it broke through a development barrier that had stumped researchers and pharmaceutical companies for nearly two decades.
What Makes TONMYA Stand Out?
TONMYA isn’t just cyclobenzaprine repackaged – it’s a completely different formulation that changes how the drug enters your system and works in your body. The sublingual tablet dissolves under your tongue at bedtime, providing rapid transmucosal absorption that bypasses first-pass hepatic metabolism. Translation? The medication gets absorbed directly through the tissues in your mouth and enters your bloodstream quickly, avoiding the initial breakdown that happens in your liver when you swallow a pill. This matters because it reduces production of norcyclobenzaprine, a long half-life active metabolite that can hang around in your system and potentially cause next-day grogginess.
The drug works as a multifunctional agent with potent binding at four different receptor types: 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors. By targeting these multiple neurotransmitter systems simultaneously, TONMYA addresses the complex neurochemical imbalances thought to drive fibromyalgia’s pain amplification. Clinical trials demonstrated that TONMYA significantly reduced daily pain scores compared to placebo at 14 weeks, and a greater percentage of participants experienced clinically meaningful pain improvement (at least 30% reduction) after three months. Across three Phase 3 trials involving over 1,400 patients, the treatment was generally well tolerated.
Perhaps most importantly for your daily life, TONMYA is taken once daily at bedtime –
Does It Really Work?
Two major Phase 3 clinical trials involving nearly 1,000 fibromyalgia patients delivered the kind of results that get the FDA’s attention. The RELIEF and RESILIENT studies weren’t small pilot programs or preliminary tests – they were full-scale, double-blind, randomised, placebo-controlled trials conducted across dozens of sites throughout the United States. And the numbers? They tell a pretty compelling story about what you might expect if you try this treatment.
Both trials hit their primary endpoint at 14 weeks, with TONMYA significantly reducing daily pain scores compared to placebo. But here’s what really matters to you… A greater percentage of people taking TONMYA experienced what doctors call a “clinically meaningful” improvement – that’s at least a 30% reduction in pain after three months. The TNX-102 SL, now the Fourth FDA-approved treatment for fibromyalgia, represents the first new option in over 15 years, which explains why the fibromyalgia community has been watching these results so closely. Across three Phase 3 trials with over 1,400 patients evaluated, the treatment was generally well tolerated, though you should know about the most common side effects – things like oral numbness, drowsiness, and mouth discomfort topped the list.
The Science Behind the Claims
What makes cyclobenzaprine different from anything you’ve tried before comes down to how it’s delivered and what it does once it gets into your system. This isn’t your typical oral medication that goes through your digestive system. The sublingual formulation (that means under your tongue) provides rapid transmucosal absorption and bypasses first-pass hepatic metabolism – basically, it gets into your bloodstream faster and avoids creating a long-lasting metabolite called norcyclobenzaprine that can hang around in your body. That’s why you’re taking it once daily at bedtime instead of multiple times throughout the day.
The real magic happens at the receptor level. TONMYA acts as a multifunctional agent with potent binding and antagonist activities at four different receptor types – 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors. These are all neurotransmitters thought to be involved in fibromyalgia’s pain amplification process. Dr Andrea Chadwick from The University of Kansas Health System points out that this multi-target approach marks a meaningful advancement because it addresses the complex neurotransmitter dysregulation that drives your symptoms. The RESILIENT trial data, published in Pain Medicine, didn’t just measure pain reduction – secondary endpoints tracked your overall impression of change, how you function day-to-day, sleep quality, and fatigue levels… because fibromyalgia isn’t just about pain, right?
Real-Life Success Stories
Sharon Waldrop, who founded the Fibromyalgia Association and lives with the condition herself, calls the availability of TONMYA a source of “new hope” for the community. That’s not just promotional talk – it’s coming from someone who understands the daily struggle of managing this disease. When you’ve been dealing with chronic widespread pain, nonrestorative sleep, and debilitating fatigue for years with limited options, having a fourth FDA-approved treatment (and the first new one since 2009) feels like someone finally remembered you exist.
The clinical trial participants who experienced that 30% or greater pain reduction weren’t just seeing numbers change on a chart. They were people like you who could finally sleep through the night without waking up exhausted, who could think more clearly during the day, who could participate in activities they’d given up on. And because TONMYA is a non-opioid treatment, you don’t have to worry about addiction potential or the stigma that sometimes comes with controlled substances
My Take on the Safety Profile
Across three Phase 3 clinical trials involving over 1,400 patients, TONMYA was generally well tolerated, which is honestly a big deal when you’re talking about a medication you’ll potentially take every night. The safety data shows a pretty clear picture of what you might experience, and most of the side effects are related to how you take this medication (under your tongue) rather than systemic issues that affect your whole body. That sublingual delivery method means you’re getting some local mouth-related effects that can feel weird but aren’t necessarily dangerous.
What I find reassuring is that the FDA approved this based on data from nearly 1,000 patients in the two pivotal trials, plus additional safety information from a third trial. That’s a substantial number of people who’ve actually used this medication in controlled settings. And because it’s non-opioid, you’re avoiding the whole addiction and dependence nightmare that comes with opioid pain medications, which is huge for a chronic condition like fibromyalgia, where you might be on treatment for years.
What Side Effects Should You Watch Out For?
The most common side effects you’ll likely encounter are all related to where the tablet sits under your tongue. Oral hypoesthesia (numbness in the mouth), oral discomfort, and abnormal product taste topped the list in clinical trials, showing up at rates of 2% or higher compared to placebo. You might also experience tingling or pricking sensations in your mouth (oral paresthesia) or straight-up oral pain. These aren’t exactly pleasant, but they’re localised and typically manageable for most people.
Beyond the mouth stuff, somnolence (drowsiness) and fatigue were also common, which makes sense since you’re taking this at bedtime anyway. Dry mouth and the occasional canker sore (aphthous ulcer) rounded out the list of frequent side effects. The drowsiness is actually somewhat intentional given the dosing schedule, but if you’re finding yourself groggy the next morning or experiencing fatigue that interferes with your daily activities, that’s definitely something to discuss with your doctor. Some people might need to adjust their timing or dosage during that initial two-week run-in period when you’re starting at the lower 2.8 mg dose.
Who Should Probably Skip It?
TONMYA comes with some serious contraindications you can’t ignore. If you’ve taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, this medication is absolutely off the table for you. The interaction between cyclobenzaprine and MAOIs can be dangerous, so there needs to be that two-week washout period. You’ll also need to skip TONMYA if you have hyperthyroidism or if you’ve recently had a heart attack – these are hard stops, not maybes.
Heart-related issues are a big concern here. If you have arrhythmias, heart block, conduction disturbances, congestive heart failure, or you’re in the acute recovery phase following a myocardial infarction, your doctor will likely steer you toward other options. The medication’s effects on cardiac conduction mean it’s not worth the risk if you’ve got underlying heart problems. And obviously, if you’re allergic to cyclobenzaprine or any of the tablet’s ingredients, that’s an automatic no-go.
There are also some warnings and precautions worth noting, even if you don’t fall into the contraindicated categories. Because cyclobenzaprine is structurally related to tricyclic antidepressants, it carries some similar risks – particularly around central nervous system effects and potential interactions with other medications. If you’re taking other CNS depressants, drinking alcohol regularly, or have liver problems, you’ll need closer monitoring. Your doctor should evaluate your complete medication list and health history before prescribing TONMYA to make sure it’s truly appropriate for your situation.
How’s It Different from Other Options?
So what makes TONMYA stand out in a crowded field of fibromyalgia treatments? Well, for starters, it’s the first FDA-approved treatment for fibromyalgia in more than 15 years. That’s a pretty significant gap when you consider how many people have been struggling with limited options during that time. The real difference comes down to how it works – TONMYA is a first-in-class, non-opioid analgesic that you take once daily at bedtime, and it works by targeting neurotransmitters thought to be involved in fibromyalgia pain. Unlike older treatments that might address symptoms indirectly, this approach goes after the core issue: widespread pain.
Your treatment landscape has been pretty stagnant for over a decade and a half, which means if you’ve been living with fibromyalgia during that time, you’ve probably cycled through the same handful of options without much innovation. TONMYA changes that equation by offering a sublingual tablet formulation that provides rapid transmucosal absorption and reduces the production of a long half-life active metabolite. Translation? It gets into your system quickly and doesn’t hang around causing problems the next day. And because it’s taken at bedtime, it works while you sleep – which is when many fibromyalgia patients struggle the most.
Comparing TONMYA to Old-School Treatments
You’re probably wondering how this stacks up against what you’ve already tried. The differences are actually pretty striking when you lay them out side by side. Traditional fibromyalgia treatments have been around for years, but they weren’t necessarily designed with fibromyalgia as the primary target – many were repurposed from other conditions. TONMYA, on the other hand, was specifically developed and tested in nearly 1,000 patients across two Phase 3 clinical trials exclusively for fibromyalgia treatment.
| TONMYA | Traditional Treatments |
| First-in-class, FDA-approved specifically for fibromyalgia in 2025 | Multiple daily doses oare ften required |
| Non-opioid analgesic taken once daily at bedtime | Systemic side effects are more common with traditional oral formulations |
| Sublingual tablet with rapid transmucosal absorption | Traditional oral tablets with first-pass hepatic metabolism |
| Targets multiple neurotransmitter receptors (5-HT2A, α1-adrenergic, H1-histaminergic, M1-muscarinic) | More limited receptor activity profiles |
| Significantly reduced daily pain scores at 14 weeks in clinical trials | Variable efficacy results across patient populations |
| Generally well-tolerated across over 1,400 patients in three Phase 3 trials | Side effect profiles vary widely by medication class |
| Most common side effects related to oral administration (numbness, tingling, taste changes) | Multiple daily doses are often required |
What really sets TONMYA apart is that it’s non-opioid, which is huge given the ongoing concerns about opioid use in chronic pain management. You don’t have to worry about addiction potential or the regulatory hurdles that come with controlled substances. Plus, the once-daily bedtime dosing means you’re not constantly thinking about your medication throughout the day – you take it, you sleep, and it works. The sublingual formulation also means it bypasses first-pass hepatic metabolism, which reduces the production of norcyclobenzaprine, a long half-life active metabolite that
Why I Think This Is a Game Changer
When you’ve been watching the fibromyalgia treatment landscape for years, you start to notice the patterns. The same three medications are getting recycled in different combinations, the same disappointing conversations with your doctor about “managing expectations.” So when something genuinely new comes along – and I mean actually new, not just a reformulation – it’s worth paying attention to. TONMYA isn’t just another option in an already crowded field. It’s the first FDA-approved treatment for fibromyalgia in more than 15 years, which honestly sounds impossible until you realise how long patients have been stuck with the same limited toolkit.
What makes this particularly significant is the timing and the science behind it. You’re looking at a treatment that was evaluated across nearly 1,000 patients in two Phase 3 trials, with data published in Pain Medicine showing improvements not just in pain scores but in how patients actually felt about their overall condition. The fact that it’s a non-opioid analgesic taken once daily at bedtime addresses two massive concerns at once – the opioid crisis that’s made doctors rightfully cautious about pain management, and the compliance issues that come with complicated dosing schedules. And because it works by targeting neurotransmitters thought to be involved in fibromyalgia through its unique sublingual formulation, you’re getting a completely different mechanism of action than what’s currently available. That’s not incremental improvement… that’s a fundamental shift in how we can approach this disease.
The Importance of New Treatment Options
Here’s what 15 years without innovation actually means for you if you’re living with fibromyalgia. It means you’ve probably tried the same three FDA-approved medications (pregabalin, duloxetine, and milnacipran) in various combinations. It means you’ve likely experienced the frustration of treatments that help some symptoms but not others, or that come with side effects you can’t tolerate. An estimated 10 million people in the U.S. are living with fibromyalgia, and roughly 80% of them are women who’ve been navigating a healthcare system that often dismisses their pain or offers solutions that barely scratch the surface of their suffering.
The ripple effects of limited treatment options go way beyond just physical pain. When you’re stuck with therapies that don’t work well enough, your quality of life tanks, your ability to work becomes compromised, and your medical costs skyrocket. In fact, patients with fibromyalgia have double the medical costs compared to the general population – partly because they’re constantly cycling through different treatments, specialists, and interventions trying to find something that works. Having a genuinely new option means you finally have another card to play when the standard treatments have failed you. It means researchers and pharmaceutical companies are paying attention again. And it means the conversation around fibromyalgia treatment can evolve beyond “let’s try adjusting your current meds” to “let’s explore a treatment designed specifically with your condition’s underlying mechanisms in mind.”
What Patients Are Saying About It
The patient community’s response has been cautiously optimistic, which honestly makes sense given how many times people with fibromyalgia have gotten their hopes up only to be disappointed. But there’s something different in the tone this time. Sharon Waldrop, founder of the Fibromyalgia Association and someone with lived experience of the condition, put it pretty directly: “The availability of TONMYA provides new hope for our community” and represents a significant step forward in treatment. That’s not just corporate speak – that’s coming from someone who’s been in the trenches advocating for patients who’ve felt forgotten by the medical establishment.
What’s particularly interesting is hearing from the clinical side, too. Dr Andrea Chadwick from The University of Kansas Health System pointed out that fibromyalgia patients have struggled with limited treatment options that often fall short for years, and she’s calling TONMYA a meaningful advancement specifically because of how it targets neurotransmitters involved in the disease. When you’ve got both patient advocates and pain specialists expressing genuine enthusiasm about the same treatment, that’s when you know something’s actually different
What’s Next for Fibromyalgia Treatments?
My friend Sarah told me last month that she’d been waiting so long for something new that she’d basically given up hope. That’s what 15 years without innovation does to people living with fibromyalgia – it creates this sense of stagnation, like the medical community just… forgot about you. But here’s the thing: TONMYA’s arrival isn’t just about one new medication hitting pharmacy shelves nationwide. It’s about breaking open a door that’s been stuck shut since 2009.
The landscape’s shifting, and you’re going to see it happen faster than you might think. With TONMYA now commercially available as the first FDA-approved fibromyalgia treatment in over 15 years, pharmaceutical companies are paying attention again. When one breakthrough happens, it tends to create momentum – suddenly investors want in, researchers dust off their proposals, and the whole ecosystem gets energised. Your treatment options in 2030 could look dramatically different from those they do today, and that’s not just wishful thinking.
Future Research and Hope for More Options
Scientists are diving deeper into fibromyalgia’s mechanisms than ever before, and what they’re finding is fascinating. TONMYA works by targeting multiple neurotransmitter systems – the 5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic receptors – which tells us something important about how complex this condition really is. You can’t just hit one target and expect everything to improve. That’s probably why earlier treatments fell short for so many people.
The RESILIENT trial data published in Pain Medicine showed improvements not just in pain scores, but in sleep disturbance, fatigue, and overall function. And that’s opening researchers’ eyes to something they should’ve realised years ago – fibromyalgia isn’t just a pain problem, it’s a central nervous system disorder with amplified sensory and pain signalling. So what’s coming next? You’ll likely see treatments that approach this from different angles… maybe targeting inflammation differently, or working on the sleep-pain cycle from another direction. The patent protection for TONMYA extends until 2034 (possibly 2044 with pending applications), which gives Tonix time to explore additional uses, but it also means other companies will be developing competing approaches. Competition’s good for you – it drives innovation and usually brings costs down eventually.
Patient Advocacy and Awareness Efforts
Sharon Waldrop, who founded the Fibromyalgia Association and lives with the condition herself, put it perfectly when she said TONMYA “provides new hope for our community.” But that statement represents something bigger than just excitement about a new drug. Patient advocacy groups have been pushing, lobbying, and making noise for years while the rest of the medical world moved on to sexier conditions. They didn’t give up, even when 10 million Americans with fibromyalgia were crucially told to make do with off-label medications and lifestyle changes.
These advocacy efforts are ramping up now that there’s actual news to share. You’re seeing partnerships between pharmaceutical companies, researchers, patients, and investigators – the kind of collaboration that should’ve been happening all along. The Fibromyalgia Association and similar groups are working to educate healthcare providers about new treatment options, because here’s an uncomfortable truth: many doctors still don’t take fibromyalgia seriously. Some still think it’s “all in your head” or that you’re just depressed. Having an FDA-approved, first-in-class treatment changes that conversation completely.
Your voice matters more than you probably realise in this space. When patient advocacy groups collect real-world data about how treatments are working (or not working), when they share stories about the daily struggle of living with chronic widespread pain and nonrestorative sleep, when they push back against insurance companies denying coverage… that’s what moves the needle. Approximately 80% of fibromyalgia patients are women, and historically, conditions that primarily affect women have been underfunded and under-researched. But advocacy efforts are slowly changing that reality, making fibromyalgia impossible to ignore and demanding that your quality of life matters just as much
Summing up
Now you’ve got the full picture on TONMYA and what it really means for fibromyalgia treatment. Unlike the recycled options patients have been stuck with for over 15 years, this is genuinely new territory – a first-in-class drug that works through a different mechanism than anything currently available. Your doctor now has a non-opioid option that targets those neurotransmitters believed to be involved in fibromyalgia pain, and it’s designed specifically for bedtime dosing. The clinical trials showed real results… significant pain reduction compared to placebo, with a good chunk of patients experiencing that 30% improvement threshold that actually makes a difference in your daily life.
But here’s what you really need to know. This isn’t a miracle cure, and no one’s claiming it is. TONMYA was generally well-tolerated in studies, though you might deal with some mouth-related side effects or drowsiness, which makes sense given when you’re taking it. If you’ve been cycling through the same old treatments without relief, this represents your first genuinely new option in a decade and a half. That’s significant. So if fibromyalgia has been controlling your life, it’s worth having a conversation with your healthcare provider about whether TONMYA might fit into your treatment plan. Because after years of making do with limited choices, you finally have something different to try.
FAQ
Q: What makes TONMYA different from regular cyclobenzaprine pills you can get at the pharmacy?
A: The delivery method changes everything here. TONMYA uses a sublingual tablet that dissolves under your tongue, which means the medication gets absorbed directly through the tissue in your mouth instead of going through your digestive system first. This matters because when regular cyclobenzaprine goes through your liver (that’s the “first-pass metabolism”), it creates a metabolite called norcyclobenzaprine that sticks around in your body for a really long time – sometimes days. With TONMYA’s sublingual delivery, you bypass most of that liver processing, so you get less of that long-lasting metabolite. The dose is also much lower than traditional cyclobenzaprine… we’re talking 5.6 mg at bedtime versus the typical 5-30 mg doses used for muscle spasms. And honestly, the FDA approved it specifically for fibromyalgia pain, which is completely different from the muscle relaxant indication that regular cyclobenzaprine has. So yeah, same active ingredient, but the formulation and how it works in your body? Totally different ballgame.
Q: Is cyclobenzaprine really considered “first-in-class” when it’s been around since the 1970s?
A: This trips people up all the time, and it’s a fair question. TONMYA is called “first-in-class” because of what it does for fibromyalgia specifically, not because cyclobenzaprine itself is new. The “class” here refers to its unique mechanism as a bedtime analgesic for fibromyalgia – it works on multiple neurotransmitter receptors (5-HT2A, alpha-1 adrenergic, H1 histaminergic, and M1 muscarinic) in a way that targets the central nervous system pain amplification that happens in fibromyalgia. No other approved fibromyalgia treatment works quite this way. Before TONMYA got approved in August 2025, the last FDA approval for fibromyalgia was over 15 years ago. Those older medications (duloxetine, milnacipran, and pregabalin) work through different mechanisms – they’re SNRIs or calcium channel modulators. So when Tonix calls TONMYA “first-in-class,” they mean it’s the first of its kind as a low-dose sublingual tertiary amine tricyclic specifically developed and approved for fibromyalgia. The sublingual formulation, the specific dosing, the bedtime timing, the receptor profile… all of that together creates something that hadn’t existed before for this condition.
Q: How well does TONMYA actually work compared to a placebo in the clinical trials?
A: The Phase 3 trials (RELIEF and RESILIENT) enrolled nearly 1,000 patients total, and TONMYA beat placebo on the primary endpoint – reducing daily pain scores at 14 weeks. But let me be real with you… The press release doesn’t give us the actual numbers, which is frustrating if you want specifics. What we do know is that a greater percentage of people taking TONMYA experienced what doctors consider a “clinically meaningful” improvement (that’s at least 30% pain reduction) after three months compared to placebo. The RESILIENT trial results were published in Pain Medicine and showed improvements not just in pain, but also in secondary measures like patient global impression of change, symptoms, function, sleep disturbance, and fatigue. There was a third trial called RALLY that showed a treatment effect favouring TONMYA, but it didn’t reach statistical significance – the company noted there were factors outside the study conduct that might’ve affected those results. Across all three Phase 3 trials with over 1,400 patients, the safety profile looked pretty consistent. So the efficacy is there, it’s FDA-approved based on that data, but like most fibromyalgia treatments, it’s not a miracle cure – it’s about meaningful improvement for many patients.
